ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Qifeng Xiao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109657055. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. Co-author DOI 10.1016/j.mcp.2025.102030 ↗
Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferroptosis via regulating SCD1-mediated unsatur… Co-author DOI 10.1186/s13062-023-00421-6 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hong-Juan Yao · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Chenyu Yuan · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Yuchen Shi · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Xiaohong Liu · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Liang Li · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Hebing Chen · 1 shared paper, 2025 · strength 0.20
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030 ↗
Shuisheng Zhang · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗
Hu Ren · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗
Shunda Wang · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗
Jianwei Zhang · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗
Dan Li · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗
Chengfeng Wang · 1 shared paper, 2023 · strength 0.17
- Paper Overexpression of ZNF488 supports pancreatic cancer cell proliferation and tumorigenesis through inhibition of ferropto… DOI 10.1186/s13062-023-00421-6 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.